The treatment landscape for ESR1-mutated metastatic breast cancer has undergone transformative changes in 2025, marked by breakthrough therapeutic advances and paradigm-shifting approaches to molecular monitoring. These developments represent a critical evolution in managing one of the most challenging aspects of HR+/HER2-negative metastatic breast cancer: endocrine resistance.
Understanding ESR1 Mutations and Their Clinical Significance
ESR1 mutations are considered a key mechanism of acquired resistance to endocrine therapy in metastatic HR+/HER2-negative breast cancer, particularly in patients treated with aromatase inhibitors and CDK4/6 inhibitors. While relatively rare in primary tumors, prevalence increases dramatically with standard-of-care treatment. Up to 40% of patients with advanced-stage ER+/HER2-negative breast cancer develop ESR1 mutations during first-line treatment with aromatase inhibitors plus CDK4/6 inhibitors.
Next-Generation Selective Estrogen Receptor Degraders
After the approval of elacestrant (Orserdu) in 2023, the most significant advancement in 2025 has been the clinical validation of multiple next-generation oral Selective Estrogen Receptor Degraders (SERDs) that demonstrate superior efficacy compared to fulvestrant in certain ESR1-mutated metastatic breast cancer, with the additional benefit of oral administration.
Camizestrant, a next-generation oral SERD and complete ER antagonist, received Breakthrough Therapy Designation from the FDA in June 2025. The SERENA-6 trial demonstrated that early detection and intervention based on circulating tumor DNA (ctDNA) monitoring for emerging ESR1 mutations can substantially improve outcomes, a major developmental accomplishment. Patients with ER+/HER2-negative disease receiving first-line aromatase inhibitors plus CDK4/6 inhibitors were frequently tested for emerging ESR1 mutations via ctDNA before showing radiographic progression. When ESR1 mutations were identified, switching to camizestrant while continuing CDK4/6 inhibitor therapy resulted in median progression-free survival of 16.0 months compared to 9.2 months for patients who continued aromatase inhibitors—a remarkable 56% reduction in risk (HR=0.44; p< .0001). For additional context on recent SERD innovations and ESR1-related findings presented at ASCO, see our 2025 ASCO highlights.
Giredestrant, a next-generation oral SERD and complete ER antagonist, in combination with oral everolimus, demonstrated a 44% reduction in disease progression or death risk in the intention-to-treat population and a striking 62% reduction in patients with ESR1 mutated metastatic breast cancer in the post-CDK4/6 inhibitor setting (evERA Trial). The median progression-free survival in ESR1-mutated patients was 9.99 months compared to 5.45 months with standard endocrine therapy plus everolimus. This combination was well tolerated and, if approved, would represent the first oral SERD combination in this setting.
Imlunestrant (Inluriyo), an oral SERD, received FDA approval in September 2025 alongside Guardant360 CDx companion diagnostic assay for adults with ER+/HER2-negative, ESR1-mutated advanced/metastatic breast cancer following progression after at least one prior line of endocrine therapy. The EMBER-3 trial demonstrated that imlunestrant monotherapy reduced the risk of progression or death by 38% compared to standard endocrine therapy in patients with ESR1 mutations. The median progression-free survival was 5.5 months for imlunestrant versus 3.8 months for endocrine therapy with fulvestrant or exemestane. Furthermore, the combination of imlunestrant with abemaciclib showed even greater benefit regardless of ESR1 mutation status, with median progression-free survival of 9.4 months
Vepdegestrant, a first-in-class, oral PROTAC ER degrader (VERITAC-2 Trial), is currently under NDA review. Vepdegestrant improved median progression-free survival in patients with ESR1-mutated tumors (5.0 months versus 2.1 months with fulvestrant). The clinical benefit rate was 42.1% with vepdegestrant versus 20.2% with fulvestrant, and the objective response rate was 18.6% versus 4.0%.
Vepdegestrant has demonstrated greater in vivo ER degradation potential than fulvestrant, and other preclinical studies have demonstrated that vepdegestrant can achieve robust tumor regression when combined with CDK4/6, mTOR, or PI3K inhibitors, making it another potential future endocrine therapy option for ESR1-mutated metastatic breast cancer. The rationale for combinations stems from understanding that ESR1 mutations represent one of several resistance pathways, and dual targeting of estrogen receptor signaling plus cell cycle or PI3K/mTOR pathways may provide a synergistic benefit.
Circulating Tumor DNA Monitoring
A transformative development has been the integration of ctDNA liquid biopsy testing into routine clinical practice. ASCO guidelines now recommend routine ESR1 mutation testing at disease recurrence or progression with blood-based ctDNA testing preferred over tissue biopsy due to greater sensitivity. The SERENA-6 trial’s success has validated ctDNA-guided treatment switching as a viable strategy, potentially establishing regulatory precedent for molecular progression triggering treatment changes rather than waiting for radiographic progression.
The PADA-1 trial provided early evidence that active monitoring of ESR1 mutations in plasma ctDNA could guide treatment decisions. Patients who displayed an ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch from an aromatase inhibitor plus palbociclib to fulvestrant plus palbociclib. This trial was the first to demonstrate benefit from a treatment-switching strategy guided by ESR1 mutation monitoring.
Conclusion
The development of oral SERDs has focused on overcoming fulvestrant’s limitations through improved pharmacokinetics, oral bioavailability, and enhanced potency against ESR1 mutations. Imlunestrant’s ability to penetrate the blood-brain barrier offers potential advantages for treating central nervous system metastases. The consistent activity of these agents across different ESR1 mutation types (eg, Y537S, Y537N, D538G) addresses the heterogeneity of resistance mechanisms. However, understanding differences among distinct ESR1 mutations and their differential responses to various therapies remains an area requiring further investigation, as different mutations may have varying effects on treatment response.
Despite remarkable progress, it remains to be seen how the progression-free survival benefits translate into overall survival advantages. As overall survival data mature and additional agents complete development, the challenge will be determining optimal treatment sequencing and identifying which patients benefit most from specific therapeutic approaches and whether ctDNA-guided early switching before radiographic progression should become standard practice.
Non-invasive monitoring of ESR1 mutation status via blood ctDNA (liquid biopsy) is now FDA endorsed and incorporated in clinical workflows using Guardant360 CDx. PADA-1 and SERENA-6 trials suggest early molecular detection (before radiographic progression) and timely therapy switch yields substantial progression-free and quality-of-life benefits. Different ESR1 mutations may variably impact outcomes and therapy responses, but research is ongoing to determine mutation-specific approaches. The FDA has requested post-marketing trials to further validate outcomes, including overall survival, in the ESR1‑mutated population. While PFS benefit is established, ongoing long-term studies, such as the EMBER‑3 postmarketing trial, will be key for survival data.
Our Allucent Center of Expertise (ACE) in Oncology supports the evolving needs of oncology drug development, providing strategic trial design, operational expertise, and biomarker-focused solutions across breast cancer and other solid tumor programs.
Request a Proposal
Share This
